Celldex Therapeutics, Inc. CLDX
Celldex Therapeutics, Inc., which we refer to as "Celldex," "we," "us," "our" or the "Company," is a biopharmaceutical company dedicated to exploring the science of mast cell biology and developing therapeutic antibodies which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Our drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
We are focusing our efforts and resources on the continued research and development of
● Barzolvolimab (also referred to as CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is currently being studied across multiple mast cell driven diseases including
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $7.0M | $6.9M | $2.4M | $4.7M | $7.4M | $3.6M | $9.5M | $12.7M | $6.8M |
| Cost of revenue | $200.0K | $200.0K | $300.0K | $100.0K | $100.0K | $200.0K | $100.0K | $700.0K | $700.0K | $1.6M |
| Gross profit | $1.3M | $6.8M | $6.6M | $2.3M | $4.6M | $7.2M | $3.5M | $8.8M | $12.0M | $5.2M |
| R&D | $245.1M | $163.6M | $118.0M | $82.3M | $53.3M | $42.5M | $42.7M | $66.4M | $96.2M | $102.7M |
| SG&A | $43.8M | $38.5M | $30.9M | $27.2M | $20.5M | $14.5M | $15.4M | $19.3M | $25.0M | $36.0M |
| Total operating expenses | $288.9M | $202.1M | $161.4M | $117.6M | $75.9M | $70.8M | $58.6M | $166.0M | $134.3M | $139.7M |
| Operating income | -$287.4M | -$195.1M | -$154.5M | -$115.2M | -$71.2M | -$63.4M | -$55.0M | -$156.4M | -$121.5M | -$132.9M |
| Pre-tax income | -$258.8M | -$157.9M | -$141.4M | -$112.3M | -$70.7M | -$60.9M | -$50.9M | -$151.9M | -$117.3M | -$128.5M |
| Income tax | $0 | $0 | $0 | — | $227.0K | $1.2M | — | $765.0K | $24.3M | — |
| Net income | -$258.8M | -$157.9M | -$141.4M | -$112.3M | -$70.5M | — | — | — | — | — |
| EPS, basic | -3.90 | -2.45 | -2.92 | -2.40 | -1.64 | -2.02 | -3.51 | — | — | — |
| EPS, diluted | -3.90 | -2.45 | -2.92 | -2.40 | -1.64 | -2.02 | -3.51 | -14.48 | -10.86 | -18.99 |
| Shares, diluted (wtd. avg.) | $66.4M | $64.4M | $48.4M | $46.9K | $42.9K | $29.6K | $14.5K | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $28.9M | $28.4M | $34.8M | $29.4M | $39.1M | $43.8M | $11.2M | $24.3M | $40.3M | $42.5M |
| Short-term investments | $489.7M | $696.9M | $388.8M | $275.5M | $369.1M | $150.6M | $53.2M | $69.7M | $99.1M | $147.3M |
| Total current assets | $534.7M | $747.2M | $431.7M | $317.7M | $410.8M | $197.8M | $66.7M | $99.1M | $144.8M | $195.6M |
| Property, plant and equipment | $5.3M | $4.3M | $4.1M | $3.7M | $3.6M | $3.8M | $4.0M | $6.1M | $10.4M | $13.2M |
| Goodwill | — | — | — | — | — | — | — | — | $91.0M | $91.0M |
| Other intangibles | $27.2M | $27.2M | $27.2M | $27.2M | $27.2M | $30.7M | $48.7M | $48.7M | $67.6M | $81.5M |
| Total assets | $583.0M | $792.3M | $465.6M | $352.7M | $444.7M | $235.8M | $122.9M | $155.8M | $315.6M | $383.4M |
| Accounts payable | $1.2M | $3.3M | $3.5M | $3.3M | $1.2M | $1.0M | $1.2M | $1.1M | $1.7M | $1.7M |
| Total current liabilities | $51.0M | $39.5M | $31.1M | $18.6M | $16.5M | $14.2M | $11.6M | $12.6M | $27.7M | $35.2M |
| Total liabilities | $55.8M | $45.3M | $36.5M | $26.5M | $25.2M | $26.5M | $28.9M | $31.7M | $79.3M | $117.9M |
| Retained earnings | -$1.81B | -$1.56B | -$1.40B | -$1.26B | -$1.14B | -$1.07B | -$1.01B | -$962.4M | -$812.5M | -$719.5M |
| Total equity | $527.2M | $747.0M | $429.2M | $326.2M | $419.5M | $209.4M | $94.0M | $124.1M | $236.4M | $265.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$210.9M | -$157.8M | -$107.3M | -$103.7M | -$60.9M | -$40.4M | -$46.4M | -$75.2M | -$99.9M | -$113.0M |
| Depreciation and amortisation | $3.4M | $3.2M | $3.0M | $2.9M | $3.1M | $3.9M | $4.9M | $3.6M | $4.4M | $3.1M |
| Stock-based compensation | $36.2M | $34.2M | $23.9M | $15.6M | $9.0M | $3.9M | $4.6M | $8.1M | $12.3M | $15.3M |
| Capital expenditure | $2.7M | $1.9M | $1.8M | $1.8M | $1.2M | $1.6M | $731.0K | $813.0K | $1.8M | $2.8M |
| Investing cash flow | $209.1M | -$290.1M | -$105.8M | $89.9M | -$216.2M | -$98.2M | $17.1M | $29.8M | $46.5M | $68.9M |
| Financing cash flow | $2.4M | $441.4M | $218.5M | $4.1M | $272.4M | $171.2M | $16.3M | $29.4M | $51.3M | $14.5M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-050884.
Others in SIC 2835
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | $42.18B | 40.9x | 10.4% |
| LNTH | Lantheus Holdings, Inc. | $6.59B | 29.6x | 0.5% |
| NEOG | NEOGEN CORP | $2.58B | — | -2.7% |
| NTLA | Intellia Therapeutics, Inc. | $1.79B | — | 16.9% |
| QDEL | QuidelOrtho Corp | $958.0M | — | -1.9% |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $873.6M | — | — |
| TKNO | Alpha Teknova, Inc. | $371.5M | — | 7.4% |
| MYGN | MYRIAD GENETICS INC | $305.1M | — | -1.6% |